S11 Ep22: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS
In this episode of the Midweek Takeaway, Phil Carroll and Kevin Hornsby are joined by Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), to break down the major news that addiction candidate SVN-015 has been accepted into the US NIH/NIDA Addiction Treatment Discovery Program — opening the door to fully funded preclinical work and potentially up to $3m per year in non-dilutive grants. Anthony also discusses progress across Solvonis’ CNS pipeline, the company’s AI-powered discovery engine, and the widening valuation gap between UK and US biotech markets.
Disclaimer & Declaration of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.